Ferrocene and ruthenium arene glycomimetics: selective galectin-1 or galectin-3 inhibitors

0576678 - ÚCHP 2024 PT eng A - Abstrakt
Hamala, Vojtěch - Karban, Jindřich - Červenková Šťastná, Lucie
Ferrocene and ruthenium arene glycomimetics: selective galectin-1 or galectin-3 inhibitors.
Abstracts Book. Porto: University of Porto, 2023. s. 117, č. článku Poster 29..
[Jenner Glycobiology and Medicine Symposium /15./. 14.06.2023-16.06.2023, Porto]
Grant CEP: GA ČR(CZ) GA23-06115S
Institucionální podpora: RVO:67985858
Klíčová slova: organometallic compounds * carbohydrates * galectins
Obor OECD: Organic chemistry

In this project, we replace the aromatic substituent in known galectin inhibitors based on LacNAc, phenylthiogalactoside and thiodigalactoside scaffolds with arene-containing organometallic structures –ferrocenes1 and ruthenium arenes2 with known antitumor properties. This results in hybrid molecules that can act as both galectin inhibitors and cytotoxic and/or antimetastatic agents. We have confirmed that both ferrocenes and ruthenium arene moieties are viable bioisosteres for planar arenes in the context of glycomimetic galectin inhibitors. Prepared organometallic inhibitors have a comparable or even better binding affinity to galectins than their nonmetallic counterparts with several compounds selective to either Gal-1 orGal-3. Prepared organometallic galectin inhibitors are nontoxic to both cancer and noncancerous cell lines, however selected ferrocene complexes show a significant in vitro antimigratory effect against invasive cancer cell lines MDA-MB-231 and SK-OV-3.
Trvalý link: https://hdl.handle.net/11104/0346126